Researchers identified 29 barriers to end-of-life care discussions, including patient and physician reluctance. Despite most patients wanting to discuss their care preferences, only a minority actually do so.
Scientists created a recombinant protein that fused heat shock proteins with ovalbumin, leading to immune response against ovalbumin-producing cancer cells. The technology could be used to develop vaccine candidates against infectious diseases like AIDS and stimulate CTL responses against cancer.
A USC study found that prostate cancer patients who use erection aids after surgery report similar levels of sexual functioning to those who haven't undergone surgery. The researchers found that erection aids allowed patients to recover their sex lives, rivaling even nerve-sparing surgery.
Researchers Andrea Cooper and Julie Inamine are investigating why Mycobacterium avium causes disease in AIDS patients despite humans not being natural hosts. The studies aim to identify genes responsible for the bacteria's virulence and develop drugs to prevent disease.
Researchers at MGH have discovered a new immune response that may help control HIV levels in the body. In a study of chronically infected individuals and long-term nonprogressors, the team found that those with strong HIV-specific helper T-cell responses had lower viral loads, suggesting a potential therapeutic target.
A study found that HIV remains in a dormant state within CD4+ lymphocytes even after treatment with triple-drug cocktail therapy. This persistence suggests individuals must continue multiple-drug therapy to prevent reactivation of the infection.
Researchers found that cytotoxic T-lymphocytes (CTLs) can recognize and target different HIV strains, suggesting a potential universal vaccine. CTLs play a key role in the immune response against HIV, with high levels seen in long-term nonprogressors and individuals who remain uninfected despite multiple exposures.
A combination of urine and blood-based tests has been found to be more sensitive in detecting HIV-1 antibodies, potentially identifying individuals with compartmentalized infections or immune responses. This breakthrough could lead to the development of a safe and effective AIDS vaccine.
Researchers at Oregon Health Sciences University have found that HIV infection of endothelial cells leads to the development of cancerous B-cells in AIDS patients. The virus disrupts normal signaling mechanisms, causing an increased number of adhesion molecules to form and support the growth of malignant cells.
Researchers have discovered a small peptide called ALX40-4C that blocks the CXCR4 coreceptor used by HIV-1 to infect T cells. This breakthrough suggests a potential new generation of combination therapies that could delay or prevent HIV infection and AIDS progression.
The FDA has approved the first phase of a new AIDS vaccine developed at St. Jude Children's Research Hospital, which aims to trigger immune responses to multiple HIV isolates using envelope proteins. The vaccine combines 23 different envelopes representing various HIV strains and is expected to last one to two years.
Researchers found that combining ganciclovir eye implants with oral ganciclovir reduces the risk of new CMV disease, Kaposi's sarcoma, and extraocular complications in AIDS patients. The study also showed a delay in median survival time among those receiving combined therapy.
Scientists at Wake Forest University Baptist Medical Center have found a way to inactivate the CCR5 co-receptor, a doorway for early-stage HIV-1 virus, on the surface of macrophages and lymphocytes. This approach could be used to treat early-stage HIV-infected individuals and potentially prevent infection.
Researchers develop novel approach to block HIV virus from invading white blood cells, potentially treating AIDS patients with genetic modification and reinfusion of immune-boosting lymphocytes. This strategy may provide a new paradigm for HIV treatment, protecting cells from infection rather than inhibiting replication.
The study aims to measure how effectively combination drug therapy works during the early stages of HIV infection, with a focus on reducing damage caused by the virus. Researchers hope to determine the optimal duration of treatment for maximum benefit and assess the impact of early treatment on immune system chemicals.
Scientists activate protein receptor to stimulate cell death in brain tumors, potentially sparing normal brain tissue. The therapy shows promise in treating nearly untreatable primary central nervous system lymphomas.
Researchers found that treating co-infections with sexually transmitted diseases (STDs) significantly reduces the amount of virus shed in semen, making transmission less likely. The study suggests widespread STD screening and therapy could be a crucial step in combating HIV/AIDS globally.
A new study reveals that tissue macrophages play a critical role in triggering the production of HIV in patients with AIDS, leading to increased virus levels despite declining CD4 T cell counts. This finding highlights the importance of controlling opportunistic infections to slow the cycle of virus production.
A study found thalidomide effective in healing 55% of HIV patients' mouth ulcers, while also improving comfort during eating. However, the treatment's potential for irreversible nerve damage and other side effects require careful monitoring.
Duke researchers found an existing class of drugs, cyclosporin and FK506, effectively stops the growth of the fungus Cryptococcus neoformans. The compounds are now being tested in animals with fungal infections.
Researchers have discovered that HIV can invade cells within any female reproductive tract organ, increasing the risk of infection. The study's findings suggest that vaccine development and disease prevention should aim to confer protection throughout the entire tract.
Scientists measured viral load in 106 HIV-infected babies from birth to 5 years of age, finding that higher viral loads predict disease severity. Early HIV blood levels may also predict outcome of progression to AIDS in children, highlighting the need for early antiretroviral therapy.
Scientists at Johns Hopkins Medicine report a test that counts AIDS viruses in blood can identify infected infants and extend their lives by starting treatment early. The test shows within a month after birth whether a baby born to an HIV-positive mother is also infected, allowing for prompt intervention.
Researchers identified three key factors that significantly boost the spread of HIV: having other STDs, multiple sexual relationships, and sex with people newly infected. Increasing STD detection and treatment, and focusing on early HIV infections can help curb the epidemic.
A potent chemokine, AOP-RANTES, has been shown to inhibit HIV-1 entry into macrophages and lymphocytes at the nanomolar level. Researchers believe this could lead to a new treatment approach for HIV/AIDS by targeting host cells to prevent viral entry.
Researchers have found that cidofovir, a new antiviral drug, can slow the progression of cytomegalovirus (CMV) retinitis, a common cause of vision loss and blindness in AIDS patients. The study showed that both low and high doses of the drug were effective, allowing for less frequent treatment compared to traditional options.
Researchers have discovered that different strains of HIV may exploit distinct immune cells through chemokine coreceptors, potentially explaining the sudden collapse of the immune system in full-blown AIDS patients. The findings could lead to new treatments by targeting these receptors.
Researchers found that HIV-infected immune cells take in more vitamin C and glucose than healthy counterparts, but extremely high levels are toxic. This study provides a foundation to understand the relationship between vitamin C, HIV infection, and cell metabolism.
Researchers found a three-drug combination of indinavir, zidovudine, and lamivudine significantly reduces AIDS symptoms and prolongs patient survival compared to two-drug combinations. The study enrolled 1,156 participants and showed a 45% reduction in disease progression events.
Preliminary results from ACTG 315 show that an antiretroviral drug cocktail can partially restore immune function in people with moderately advanced HIV disease. The study found increases in CD4+ T cell counts, decreased plasma levels of HIV, and improved immune response.
Researchers found that viral load in semen increases with progression of the disease in most patients. Using antiviral therapy, they were able to reduce viral load in semen to undetectable levels in six patients.
The new Moore Options program uses AIDS specialists as primary care providers and coordinators, focusing on complex patient needs. Published studies show improved outcomes and lower costs for patients treated by experienced care providers.
Yale University has granted an exclusive license to ArQule Inc. for the development of patent-pending discoveries that could help fight various diseases, including AIDS and emphysema. The Yale chemists' method allows rapid synthesis of alpha-ketoamide-based compounds, which have shown potential in blocking key enzymes called proteases.
Researchers at Johns Hopkins Medicine discovered a link between nitric oxide levels and the severity of AIDS dementia. The study found that high levels of nitric oxide synthase in the brains of patients with advanced HIV infection led to brain cell destruction, affecting 20% of those affected.
Recent advances in HIV research reveal the critical role of host factors in determining disease progression and replication rates. Key discoveries include the regulation of HIV replication by immune response molecules and the activation of the immune system by the virus.
A recent study published in The Lancet found that a specific HIV vaccine, MNrgp120, did not stop the virus from reproducing or slow immune system destruction. Researchers evaluated 568 volunteers infected with HIV and found no significant differences in CD4 counts between those who received the vaccine and those who received a placebo.
Emory University researchers identified a subpopulation of HIV-infected infants with a thymic-defect profile, characterized by low CD4+ and CD8+ T cell counts. These high-risk infants were found to develop AIDS symptoms sooner and have increased mortality rates compared to those without the profile.
A CU-Boulder research team has identified two yeast genes, SAS2 and SAS3, closely linked to a family of human genes associated with severe leukemia and HIV-1. The discovery may help researchers better understand the causes of acute myeloid leukemia and AIDS.
Researchers found that a glass of orange juice boosts stomach acid levels and increases the absorption of delavirdine, a promising new AIDS drug. The study, funded by NIH and Upjohn Pharmaceuticals, suggests that orange juice may help patients with low stomach acid achieve adequate therapeutic benefits.
A Johns Hopkins study found that declining testosterone levels in HIV-positive men can predict weight loss and increased risk of death. Researchers measured testosterone in 26 men and discovered a significant decline in hormone levels among those who experienced weight loss.